Literature DB >> 3096741

Synthetic peptides and beta-chain gene rearrangements reveal a diversified T cell repertoire for a lambda light chain third hypervariable region.

B Bogen, R Snodgrass, J P Briand, K Hannestad.   

Abstract

Twelve L3T4+ Ly-2.2- subclones, derived from 4 independent BALB/c T cell lines, responded to a combination of the I-Ed molecule and a synthetic peptide corresponding to residues 91-108 of the lambda light chain from BALB/c myeloma protein M315 (alpha, lambda 2). Peptide analogues in which the mutated residues Arg95 or Asn96 were exchanged with the corresponding germ-line-encoded Ser95 or Thr96 had an abolished or greatly reduced capacity to stimulate T cell clones. However, responses of subclones to an analogue where the mutated Phe94 was substituted with the germ-line-encoded Tyr94 revealed three specificity patterns: 5 clones reacted only with the lambda 2(315) peptide, 6 clones responded equally well to both peptides and a single clone reacted better with the Tyr94 analogue. Analysis of the T cell receptor beta-chain gene rearrangements disclosed 7 distinct rearrangements, identical rearrangements only being found for subclones originating from the same line. At least 3 different V beta genes were used. Subclones with identical or nearly identical peptide specificity, major histocompatibility complex-restriction and alloreactivity could differ in their V beta or J beta gene segment utilization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096741     DOI: 10.1002/eji.1830161111

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  No recombinations between Tcra-V and Tcra-C gene segments in 669 backcross mice.

Authors:  L Gleditsch; R Snodgrass; B Bogen
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.

Authors:  S Weiss; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 3.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA.

Authors:  Kristin S Gunnarsen; Elin Lunde; Per E Kristiansen; Bjarne Bogen; Inger Sandlie; Geir Å Løset
Journal:  BMC Biotechnol       Date:  2010-02-03       Impact factor: 2.563

5.  Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.

Authors:  B Bogen; J D Lambris
Journal:  EMBO J       Date:  1989-07       Impact factor: 11.598

6.  DeltaPhage--a novel helper phage for high-valence pIX phagemid display.

Authors:  Nicolay R Nilssen; Terje Frigstad; Sylvie Pollmann; Norbert Roos; Bjarne Bogen; Inger Sandlie; Geir Å Løset
Journal:  Nucleic Acids Res       Date:  2012-04-26       Impact factor: 16.971

7.  Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.

Authors:  Heidi Cecilie Larsen Spång; Ranveig Braathen; Bjarne Bogen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  B-cell lymphomas present immunoglobulin neoantigens.

Authors:  Michael S Khodadoust; Niclas Olsson; Binbin Chen; Brian Sworder; Tanaya Shree; Chih Long Liu; Lichao Zhang; Debra K Czerwinski; Mark M Davis; Ronald Levy; Joshua E Elias; Ash A Alizadeh
Journal:  Blood       Date:  2018-12-13       Impact factor: 25.476

9.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

10.  Clonal deletion of specific thymocytes by an immunoglobulin idiotype.

Authors:  B Bogen; Z Dembic; S Weiss
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.